Proactive Investors Chinese | Cellmid's midkine antibodies show effectiveness against cancer Proactive Investors Chinese Cellmid Limited (ASX: CDY) has completed several studies that demonstrate its lead anti-midkine (MK) antibodies efficacy in reducing cancer tumour growth and spread. The antibodies also slowed the formation of new blood vessels (angiogenesis) in ... |
